Ellume Announces $231.8 Million Agreement with the U.S. Government to Scale Up Production of COVID-19 Home Tests

Formzoo is so incredibly excited, that a team we’re so proud to be a part of, has reached such a momentous milestone.

The contract includes the delivery of 8.5 million Ellume COVID-19 Home Tests to support the U.S. Government’s pandemic response

  • The investment will support the establishment of Ellume’s first U.S. manufacturing facility, increasing Ellume’s global production capacity by 500,000+ tests per day once completed;
  • The investment extends Ellume’s engagement with the U.S. government following the NIH RADx announcement last year;
  • The Ellume COVID-19 Home Test is the first non-prescription over-the-counter self-test authorized by the U.S. Food and Drug Administration

Digital diagnostics company Ellume today announced a $231.8 million agreement with the U.S. Department of Defense (DOD), in coordination with the Department of Health and Human Services (HHS), to accelerate domestic US production of its COVID-19 home tests.

The Ellume COVID-19 Home Test is the first rapid self-test for COVID-19 detection authorized by the U.S. FDA for both asymptomatic and symptomatic use without a prescription. With the CDC reporting that at least 50% of COVID-19 cases are transmitted asymptomatically, Ellume’s test will play a crucial role as the only diagnostic tool authorized for non-prescription use as a screening tool in the United States.

The agreement includes funding to support the establishment of Ellume’s U.S.-based manufacturing facility and the delivery of 8.5 million COVID-19 home tests that will be distributed across the U.S. in accordance with the National Strategy for the COVID-19 Response and Pandemic Preparedness plan.

This US-based manufacturing capacity builds upon Ellume’s existing Australian production capacity which is on-track to procure approximately 200,000 tests per day this quarter. Under the agreement, Ellume will be delivering 100,000 tests per month from the Australian manufacturing facility until the U.S. facility is built. At full capacity, the U.S facility will be able to produce up to 19 million tests per month.

Original Article: Ellume Health

Posted on February 1, 2021 in Design, Products, Strategy

Nail Snail - Good Design Award Winner

A Celebration of Women in Design

In honour of International Women’s Day we wanted to take the time to celebrate a Good Design alumnus, the founder of Nail Snail baby nail trimmer, Julia Christie. This time, one year ago, we had the privilege of entering the Nail Snail into the Good Design Awards on Julia’s behalf. Not only did she walk away with a Good Design award, but she has picked up a number of additional accolades over the last 12 months. Julia’s business has moved from strength to strength since its inception, and she has celebrated several milestones during the last 12 months; including the procurement of large retail partners and international distributors, as well as welcoming additional members to her team. Congratulations Julia on your inspirational growth, we look forward to watching the continued evolution of the Nail Snail.

One of the most coveted awards in the Australian and international design community, the 2019 Good Design Award entries are open until the 28th of March.
The Good Design Awards recognises and celebrates excellence in cutting edge design and breakthrough innovation. Keep an eye out for this years Good Design Winners.

Posted on March 8, 2019 in Uncategorized

Back to Top